#Ireland #Dublin #Alkermes #VIVITROL #ARISTADA

Alkermes plc Reports Second Quarter 2025 Financial Results

Dublin, Ireland — Alkermes plc (Nasdaq: ALKS) has reported its financial results for the second quarter of 2025, demonstrating robust performance with revenues amounting to $390.7 million. The company’s net income from continuing operations stood at $87.1 million, translating to diluted GAAP earnings per share of $0.52.

Richard Pops, Chief Executive Officer of Alkermes, expressed satisfaction regarding the results, noting, "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation." He emphasized the significance of the recent positive topline results from the Vibrance-1 study, which included data from their phase 2 study of alixorexton (ALKS 2680) in patients with narcolepsy type 1. These developments underscore the potential of orexin 2 receptor agonists in revolutionizing narcolepsy treatment.

Financial Overview

The second quarter revenues, while slightly below the previous year's figure of $399.1 million, showcased substantial improvement in proprietary net sales. Notable highlights include:

• - VIVITROL®: Generated $121.7 million, up 9% compared to Q2 2024.
• - ARISTADA®: Reported $101.3 million, also 18% higher than last year's quarter.
• - LYBALVI®: Recorded revenues of $84.3 million, representing an 18% increase compared to the same period in 2024.

Furthermore, Alkermes noted adjusted EBITDA for the quarter at $126.5 million, showing a decrease from $135.3 million a year earlier, yet still indicative of healthy operational performance.

Key Details and Expectations

For the first six months of 2025, the company reported total revenues of $697.2 million, compared to $749.5 million in the previous year. The total proprietary net sales increased to $551.7 million, up from $502.8 million in 2024. Additionally, the company's operations brought in cash, cash equivalents, and total investments amounting to $1.05 billion, a notable rise from $916.2 million as of March 31, 2025.

In conjunction with the positive financial results, Alkermes reiterated its financial expectations for 2025, as stated earlier in their press release on February 12. Looking ahead, the company is gearing up to launch a global phase 3 program for alixorexton and anticipates presenting detailed results from the Vibrance-1 study at the forthcoming World Sleep Congress.

Conclusion

Alkermes plc continues to make significant strides in both financial performance and product development, particularly within its neuroscience portfolio. With promising results from ongoing clinical trials, the company is well-positioned for future growth as it advances treatments for opioid dependence, schizophrenia, and narcolepsy. Investors and stakeholders are encouraged to stay tuned for updates as Alkermes hosts a conference call on July 29, 2025, to further discuss these impressive results and future outlooks.